Several large pharmaceutical firms apparently are passing over the opportunity to buy Swiss biotech Serono, a situation that may cause the company to reduce its asking price. Serono has held talks with Novartis, GlaxoSmithKline, Pfizer and others, but none put in a final bid by last Friday's bidding deadline, apparently citing the takeover's cost, according to unnamed sources.

Related Summaries